DNA methylation marks on ctDNA can be used to distinguish PCa phenotypes (Beltran et al, 2016; Beltran et al, 2020) and identify potential candidates for combination therapies such as DNMTi with B7-H3 or PSMA ADCs. The gene discussed is FOLH1; the disease is posterior cortical atrophy.